Clinical Applications of Antisense Oligonucleotides in Cancer: A Focus on Glioblastoma

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2024 Nov 27

PMID 39594617

Authors

Alexandre Khuu

Maite Verreault

Philippe Colin

Helene Tran

Ahmed Idbaih

Affiliations

Soon will be listed here.

Abstract

Antisense oligonucleotides (ASOs) are promising drugs capable of modulating the protein expression of virtually any target with high specificity and high affinity through complementary base pairing. However, this requires a deep understanding of the target sequence and significant effort in designing the correct complementary drug. In addition, ASOs have been demonstrated to be well tolerated during their clinical use. Indeed, they are already used in many diseases due to pathogenic RNAs of known sequences and in several neurodegenerative diseases and metabolic diseases, for which they were given marketing authorizations (MAs) in Europe and the United States. Their use in oncology is gaining momentum with several identified targets, promising preclinical and clinical results, and recent market authorizations in the US. However, many challenges remain for their clinical use in cancer. It seems necessary to take a step back and review our knowledge of ASOs and their therapeutic uses in oncology. The objectives of this review are (i) to summarize the current state of the art of ASOs; (ii) to discuss the therapeutic use of ASOs in cancer; and (iii) to focus on ASO usage in glioblastoma, the challenges, and the perspective ahead.

Citing Articles

Canonical and non-canonical functions of the non-coding RNA component (TERC) of telomerase complex.

Cao C, Gong W, Shuai Y, Rasouli S, Ge Q, Khan A Cell Biosci. 2025; 15(1):30.

PMID: 40025596 PMC: 11871756. DOI: 10.1186/s13578-025-01367-0.

References

Lendvai G, Velikyan I, Estrada S, Eriksson B, Langstrom B, Bergstrom M . Biodistribution of 68Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat chromogranin-A. Oligonucleotides. 2008; 18(1):33-49. DOI: 10.1089/oli.2007.0104. View

Hagedorn P, Yakimov V, Ottosen S, Kammler S, Nielsen N, Hog A . Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern. Nucleic Acid Ther. 2013; 23(5):302-10. PMC: 3760025. DOI: 10.1089/nat.2013.0436. View

Jafri M, Ansari S, Alqahtani M, Shay J . Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016; 8(1):69. PMC: 4915101. DOI: 10.1186/s13073-016-0324-x. View

Rahimi R, Leof E . TGF-beta signaling: a tale of two responses. J Cell Biochem. 2007; 102(3):593-608. DOI: 10.1002/jcb.21501. View

Hanson P, Cashikar A . Multivesicular body morphogenesis. Annu Rev Cell Dev Biol. 2012; 28:337-62. DOI: 10.1146/annurev-cellbio-092910-154152. View

Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A . Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides. 2007; 17(2):201-12. DOI: 10.1089/oli.2006.0053. View

Cieslik M, Chinnaiyan A . Cancer transcriptome profiling at the juncture of clinical translation. Nat Rev Genet. 2017; 19(2):93-109. DOI: 10.1038/nrg.2017.96. View

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

Mathews D, Turner D . Prediction of RNA secondary structure by free energy minimization. Curr Opin Struct Biol. 2006; 16(3):270-8. DOI: 10.1016/j.sbi.2006.05.010. View

10.

Yu R, Kim T, Hong A, Watanabe T, Gaus H, Geary R . Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos. 2006; 35(3):460-8. DOI: 10.1124/dmd.106.012401. View

11.

Zhang H, Mao J, Zhou D, Xu Y, Thonberg H, Liang Z . mRNA accessible site tagging (MAST): a novel high throughput method for selecting effective antisense oligonucleotides. Nucleic Acids Res. 2003; 31(14):e72. PMC: 167646. DOI: 10.1093/nar/gng072. View

12.

Caruso G, Caffo M . Antisense oligonucleotides in the treatment of cerebral gliomas. Review of concerning patents. Recent Pat CNS Drug Discov. 2014; 9(1):2-12. DOI: 10.2174/1574889809666140307113439. View

13.

Geary R, Wancewicz E, Matson J, Pearce M, Siwkowski A, Swayze E . Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochem Pharmacol. 2009; 78(3):284-91. DOI: 10.1016/j.bcp.2009.04.013. View

14.

Schlingensiepen K, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B . Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2005; 17(1-2):129-39. DOI: 10.1016/j.cytogfr.2005.09.002. View

15.

Reilley M, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y . STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018; 6(1):119. PMC: 6240242. DOI: 10.1186/s40425-018-0436-5. View

16.

Agrawal S . Antisense oligonucleotides: towards clinical trials. Trends Biotechnol. 1996; 14(10):376-87. DOI: 10.1016/0167-7799(96)10053-6. View

17.

Geary R, Norris D, Yu R, Bennett C . Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev. 2015; 87:46-51. DOI: 10.1016/j.addr.2015.01.008. View

18.

Poltronieri P, Sun B, Mallardo M . RNA Viruses: RNA Roles in Pathogenesis, Coreplication and Viral Load. Curr Genomics. 2016; 16(5):327-35. PMC: 4763971. DOI: 10.2174/1389202916666150707160613. View

19.

Khormaee S, Choi Y, Shen M, Xu B, Wu H, Griffiths G . Endosomolytic anionic polymer for the cytoplasmic delivery of siRNAs in localized applications. Adv Funct Mater. 2013; 23(5). PMC: 3834980. DOI: 10.1002/adfm.201201945. View

20.

Joseph J, Balasubramaniyan V, Walenkamp A, Kruyt F . TGF-β as a therapeutic target in high grade gliomas - promises and challenges. Biochem Pharmacol. 2012; 85(4):478-85. DOI: 10.1016/j.bcp.2012.11.005. View